Infinair 10/5mg Tablet is a combination medication containing Levocetirizine 5mg and Montelukast 10mg, indicated for the management of allergic conditions such as allergic rhinitis and chronic urticaria. Levocetirizine, a potent third-generation non-sedating antihistamine, selectively inhibits peripheral H1 receptors, thereby reducing symptoms like sneezing, nasal congestion, rhinorrhea, and itching. Montelukast, a leukotriene receptor antagonist, blocks the cysteinyl leukotriene receptor, mitigating airway inflammation and bronchoconstriction commonly associated with asthma and allergic rhinitis. The synergistic action of these two agents provides comprehensive relief from allergy symptoms by targeting multiple inflammatory pathways. Infinair is typically prescribed once daily, with or without food, and is well tolerated with a low incidence of adverse effects. Common side effects may include headache, fatigue, dry mouth, and gastrointestinal discomfort. Caution is advised in patients with hepatic impairment or a history of neuropsychiatric events. This combination therapy is not recommended for acute asthma attacks or anaphylaxis. Infinair 10/5mg Tablet offers an effective and convenient therapeutic option for patients requiring dual-action treatment for allergic respiratory conditions, enhancing symptom control and improving quality of life.